Uric acid regulatory pathways

Uric acid regulatory pathways encompass the integrated physiological processes responsible for the production, transport, and excretion of uric acid, the final breakdown product of purine metabolism in humans (StatPearls, 2023). The pathway involves the enzyme xanthine oxidase, which catalyzes the conversion of hypoxanthine and xanthine into uric acid, primarily in the liver. Urate levels are maintained through a balance of production and elimination, with approximately 70% of excretion occurring via the kidneys and 30% through the intestines (Nature Reviews Rheumatology, 2014). Key molecular components include renal transporters such as Solute carrier family 22 member 12 (URAT1) and Solute carrier family 2 member 9 (GLUT9), which mediate reabsorption, and ATP-binding cassette sub-family G member 2 (ABCG2), which facilitates secretion (Journal of Human Genetics, 2009). Dysregulation of these pathways leads to hyperuricemia, the underlying cause of gout and a contributor to nephrolithiasis and metabolic syndrome (NIH/NCBI, 2023). Therapeutic interventions target specific nodes in these pathways, such as inhibiting xanthine oxidase to lower production or blocking URAT1 to enhance renal clearance, aiming to maintain serum urate below saturation levels to prevent crystal deposition.

Other names

Urate homeostasisPurine catabolic pathwayUrate transport systemUric acid metabolism

Drugs modulate these pathways by inhibiting xanthine oxidase to reduce uric acid production, blocking renal transporters like URAT1 to increase urate excretion (uricosurics), or providing recombinant urate oxidase to metabolize uric acid into allantoin.